Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on ...
Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.
Intellia Therapeutics (NTLA) stock jumps as Evercore ISI upgraded the company on a hypothesis behind a safety signal related ...
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 0.00% and -47.22%, respectively, for the quarter ...
Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA ...
Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both ...
Intellia's peak HAE market share is estimated at just 4%, reflecting patient hesitancy for one-time gene edits. Learn why ...
Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.
Discover the top gene editing stocks to watch. Learn about this groundbreaking field and the companies leading advancements ...
Shares of Intellia Therapeutics NTLA have rallied sharply over the past month, supported by positive regulatory and clinical milestones for one of its lead candidates, lonvoguran ziclumeran (lonvo-z; ...
Is NTLA a good stock to buy? We came across a bullish thesis on Intellia Therapeutics, Inc. on Markman Capital Insight’s Substack. In this article, we will summarize the bulls’ thesis on NTLA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results